在社区环境中进行放射性瘤学同行评审:前性评审的价值
Irena Dragojević1, David Hoopes1, Gina Mansy1
1Department of Radiation Medicine & Applied Sciences UC San Diego Health 3855 Health Sciences Drive MC 0843 La Jolla, CA 92093-1503.
概括
在放射性瘤学中,前性同行评审比回顾性评审更有效,导致治疗计划更频繁,更有影响力的调整. 建议进行个性化,综合性审查,以获得最佳的质量改进.
科学领域:
- 辐射瘤学 辐射瘤学
- 提高质量 提高质量
- 医学物理 医学物理
背景情况:
- 同行评审对于辐射瘤学的持续质量改进至关重要.
- 目前的同行评审实践缺乏标准化的指导方针,导致机构的变化.
- 前性与后性同行评审的有效性仍然不清楚.
研究的目的:
- 描述与辐射瘤学同行评审的机构经验.
- 为了比较前性和后性同行评审的有效性.
- 通过故障模式和效应分析 (FMEA) 分析同行评审过程.
主要方法:
- 从2015年到2020年跟踪同行评审会议和治疗计划的变化.
- 对前性和后性审查之间的计划修改率和严重性的比较.
- 与医生和物理学家一起进行了同行评审过程的FMEA.
主要成果:
- 审查了3691名患者,51.6%接受了前性审查.
- 前性审查导致计划变更的可能性是4.5倍 (0.9%对0.2%).
- 治疗后的计划变化比治疗前的变化更严重.
结论:
- 未来的同行评审是优化放射瘤治疗计划的首选.
- 个别的综合审查任务可以增强坦率性并确保未来的报道.
- 解决潜在的障碍,如潜意识不愿改变正在进行的治疗是关键.
更多相关视频
06:20Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
Published on: March 11, 2021
7.3K
08:25Radiation Planning Assistant - A Streamlined, Fully Automated Radiotherapy Treatment Planning System
Published on: April 11, 2018
15.3K
相关概念视频
01:29Positron Emission Tomography
4.2K
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
4.2K
02:49Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K